Louis Garguilo's Articles
-
A CDMO's Mission For The Pursuit Of Rare Diseases
3/27/2023
I understand why the INADcure Foundation, led by co-founder and mother of a daughter with Infantile Neuroaxonal Dystrophy, selected its CDMO … but why would a CDMO select the foundation as a customer? I spoke to the CEO to find out.
-
A Mother Picks A CDMO To Advance Treatment For Her Daughter
3/20/2023
Until her daughter was diagnosed with Infantile Neuroaxonal Dystrophy (INAD) in 2016, Leena Panwala had been content with her life as a new mom, and selling real estate as a profession. Today, she’s co-founder and president of INADcure Foundation, and outsourcing a novel gene therapy.
-
Women Rising In Biotech
3/13/2023
Recent studies show women in the pharma industry represent 61% of the workforce, considerably higher than other industries. However, the percentage of female leaders is significantly lower. I spoke to an up-and-coming professional about this.
-
A Third Model For Outsourcing Development And Manufacturing
3/8/2023
Biopharma organizations are often counseled to consider the strategy of “mirroring” your outsourcing activities. But what if this were the other way around – your CDMO effectively mirrored your organization? It’s an idea come to life via a partnership development management organization (PDMO) in Aguadilla, Puerto Rico.
-
Lentiviral Vectors And The Island Of Partnerships
3/1/2023
You need lentiviral vectors. Apparently, so do a lot of others. Demand for lentiviral vectors is estimated to surge at a compound annual growth rate (CAGR) of 11.4 % until 2032. I’ve learned of a location where you can grab some capacity – and related CGT services.
-
Moderna And The Building Of Bridge Facilities
2/27/2023
In August of 2021, relatively overlooked because of other news swirling around our industry, Moderna became the anchor client in a new cleanroom on demand housed in a bridge facility in Massachusetts. In retrospect, it may have legitimized a new era in outsourcing.
-
6 CDMO Selection Tips From An Experienced Start-Up
2/20/2023
Does your process to select a CDMO emerge from within and without? Ryan Crisman, cofounder and Chief Technical Officer, Umoja Biopharma, Inc., says it should. And he's learned that from a wise consultant that became his full-time employee. Here are their 6 tips to successful CDMO partnerships.
-
Building In Boulder – A Biotech Finds A Manufacturing Base
2/13/2023
If any of you have thoughts of building internal development and manufacturing facilities (to supplement or augment your outsourcing,) this is a discussion for you. It describes how on cell-therapy company made key decisions.
-
A Bridge To Capacity For The Cell & Gene Industry
2/8/2023
Bridge facilities have been built for cell and gene therapy (CGT) sponsors – and CDMOs – to access here-and-now available, fully outfitted GxP capacity. But bring your own skilled workers. Here's how it works.
-
Solving The Equation For A Cell Therapy Development Strategy
2/3/2023
Nowadays, “biotechs” emerge with unique business models, are hybrids of one kind or another, and operate as developers, platform/technology creators and service providers rolled up into one glorious organization. I found another one at Umoja Biopharma, Inc., a Seattle, Washington-based cell-therapy company.